Control Of Dyslipidemia Research Articles

How Did the Updated 2019 European Society of Cardiology/European Atherosclerosis Society Risk Categorization for Patients with Diabetes Affect the Risk Perception and Lipid Goals? A Simulated Analysis of Real-life Data from EPHESUS Study.

The recent 2019 European Society of Cardiology/European Atherosclerosis Society practice guidelines introduced a new risk categorization for patients with diabetes. We aimed to compare the implications of the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines with regard to the lipid-lowering treatment use, low-density lipoprotein cholesterol goal attainment rates, and the estimated proportion of patients who would be at goal in an ideal setting. Patients with diabetes were classified into 4 risk categories according to 2019 European Society of Cardiology/European Atherosclerosis Society dyslipidemia guidelines from the database of EPHESUS (cross-sectional, observational, countrywide registry of cardiology outpatient clinics) study. The use of lipid-lowering treatment and low-density lipoprotein cholesterol goal attainment rates were then compared according to previous and new guidelines. This analysis included a total of 873 diabetic adults. Half of the study population (53.8%) were on lipid-lowering treatment and almost one-fifth (19.1%) were on high-intensity statins. While low-density lipoprotein cholesterol goal was achieved in 19.5% and 7.5% of patients, 87.4% and 69.6% would be on target if their lipid-lowering treatment was intensified according to 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society lipid guidelines, respectively. The new target <55 mg/dL could only be achieved in 2.2% and 8.1% of very high-risk primary prevention and secondary prevention patients, respectively. The control of dyslipidemia was extremely poor among patients with diabetes. The use of lipid-lowering treatment was not at the desired level, and high-intensity lipid-lowering treatment use was even lower. Our simulation model showed that the high-dose statin plus ezetimibe therapy would improve goal attainment; however, it would not be possible to get goals with this treatment in more than one-third of the patients.

Hipomagnezijemija i dijabetes melitus tipa 2

Hypomagnesemia is a relatively common and often unrecognized electrolyte disorder in type 2 diabetes mellitus. This review presents the pathophysiology of magnesium deficiency in type 2 diabetes mellitus, its role in the development of disease complications, and the effect of magnesium supplementation. The literature search was conducted using the following keywords: magnesium, diabetes mellitus, complications, supplementation, within PubMed, Emabase, Scopus, SCIndex and Hrčak for the period from 2001 to 2023. Type 2 diabetes mellitus causes increased excretion of magnesium in the urine. On the other hand, reduced concentrations of magnesium in the blood of people with type 2 diabetes mellitus predispose to complications of the disease. A significant number of randomized, controlled studies and meta-analyses indicate the beneficial effect of magnesium supplementation in the control of hyperglycemia, dyslipidemia, and hypertension in people with type 2 diabetes mellitus. Routine monitoring and correction of magnesium concentrations in the blood of people with type 2 diabetes mellitus can help control and delay complications. diseases. Further research is needed to establish firm guidelines for clinical practice.

S-53-1: SOCIOECONOMIC FACTORS AND PREVENTION OF CARDIOVASCULAR DISEASES IN ASIA

Focus on social determinants of health is important for primordial and primary prevention of cardiovascular diseases (CVD). There are multiple social determinants and are macrolevel factors: social and human development, location related factors, and policies that influence rural and urban planning, environmental pollution, healthcare infrastructure, health financing, quality of health systems, taxation on harmful products (tobacco, alcohol, trans fats), and subsidizing healthy foods. Individual level factors are: multiple social factors, education, income, employment, stress, early life events, addictions including tobacco, and availability, affordability and adherence to medicines and healthy lifestyles. Studies have shown that countries with better development have lower CVD incidence and mortality, also in Asia. Healthy lifestyles (healthy diet, physical activity, tobacco control) and awareness, treatment and control of major risk factors (hypertension, diabetes, dyslipidemias) are more in better developed Asian countries due to better health systems and universal health coverage policies. At individual level higher socioeconomic status and better educational level are associated with lower prevalence of CVD risk factors and better treatment and control of hypertension, dyslipidemias and diabetes. Interventions to address social determinants are limited and include focus on political, economic and social interventions. UN Sustainable Development Goals related to poverty eradication, zero hunger, good health and wellbeing, quality education, gender equality, decent work, economic growth, reduced inequalities, sustainable communities, responsible consumption or production, and climate action address social determinants of health. Creation of health infrastructure in rural and deprived locations, macrolevel financing, manpower deployment and workforce training are important evidence-based interventions. Interventions to improve quality of general education and health literacy and education of medical professionals and non-physician health workers have shown to ameliorate CVD related disparities. Public health interventions include life-course approach for prevention and control of risk factors, better and safe facilities for promotion of physical activity, tobacco, smoking and alcohol control policies, taxation on trans fats, sugars, sugar-sweetened beverages and salt, universal health care focussed on early CVD diagnosis and management, availability of medicines and focus on technological innovations to promote adherence to medicines and healthy lifestyles. At the individual level better CVD risk-factor control can be achieved by focus on individual social determinant and improved professional-patient communication via professional medical education, health worker related focus, patient health literacy, and greater patient involvement.

Hypotriglyceridemic and hepatoprotective effect of pumpkin (Cucurbita moschata) seed flour in an experimental model of dyslipidemia

This study evaluated the effect of pumpkin ( Cucurbita moschata ) seed flour on the lipid profile and biomarkers of liver function in an experimental dyslipidemia. The hamsters were divided into three groups: normal control group (n = 8) fed commercial feed; dyslipidemia control group (n = 8) with dyslipidemia induced by consumption of feed enriched with saturated fat and cholesterol (dyslipidemic diet with 13.5% coconut fat and 0.1% cholesterol); pumpkin seed group (n = 10), maintained on a dyslipidemic diet plus pumpkin seed flour. After 28 days of treatment, the treatment with a diet enriched with pumpkin seeds significantly reduced the serum triglycerides, increased the faecal excretion of cholesterol, and reduced the accumulation of lipids in the hepatocytes, thus decreasing the degree of hepatic steatosis. In the experimental model used in this study, pumpkin seed flour had a hypotriglyceridemic property and a hepatoprotective effect in relation to hepatic steatosis. • Feeding enriched with pumpkin seeds reduced the serum triglycerides level. • Creole pumpkin seed flour increased the excretion of cholesterol in the faeces. • Pumpkin seeds reduced the degree of hepatic steatosis.

Retinopathy of prematurity: Metabolic risk factors.

At preterm birth, the retina is incompletely vascularized. Retinopathy of prematurity (ROP) is initiated by the postnatal suppression of physiological retinal vascular development that would normally occur in utero. As the neural retina slowly matures, increasing metabolic demand including in the peripheral avascular retina, leads to signals for compensatory but pathological neovascularization. Currently, only late neovascular ROP is treated. ROP could be prevented by promoting normal vascular growth. Early perinatal metabolic dysregulation is a strong but understudied risk factor for ROP and other long-term sequelae of preterm birth. We will discuss the metabolic and oxygen needs of retina, current treatments, and potential interventions to promote normal vessel growth including control of postnatal hyperglycemia, dyslipidemia and hyperoxia-induced retinal metabolic alterations. Early supplementation of missing nutrients and growth factors and control of supplemental oxygen promotes physiological retinal development. We will discuss the current knowledge gap in retinal metabolism after preterm birth.

Sex disparities and dyslipidemic control in a coronary rehabilitation program

Lipid control is one of the most important secondary cardiovascular prevention targets. Although cardiovascular disease is the most common cause of death in both sexes, women are less likely to receive guideline-recommended secondary prevention medications. To compare sex disparities in dyslipidemia control in a secondary prevention population, we retrospectively analysed all patients who participated in a Coronary Rehabilitation Program (CRP) after an acute coronary syndrome (ACS) from January 2011 to October 2019. Of a total of 881 patients enrolled, mean age 55.0-year-old, 16.1% were female. At hospital admission, females and males had similar mean LDL-levels. Female patients received more high intensity therapy during follow-up (67.8% vs 53.9% at baseline, p = 0.015; 75.6% vs 59.0% after CRP, p = 0.003; and 79.8% vs 65.1% at 1-year-follow-up, p = 0.007). At the end of the CRP, male patients exhibit a better control of LDL [82.0 vs 75.6 mg/dL, t(597) = 2.4, p = 0.016)] with 12.8% vs 16.4% below 55 mg/dL and 29.8% vs 44.5% below 70 mg/dL (p = 0.008). At 1-year follow-up, both sexes exhibited similar LDL-control thanks to a worsening control of the male population (81.9 vs 80.6 mg/dL, t(540) = 0.52, p = 0.605). Only 13.3% of females had LDL below 55 mg/dL (vs 12.9%, p = 0.921) and 32.5% below 70 mg/dL (vs 37.0%, p = 0.432). This real-life study showed that guideline recommended LDL target is not achieved in the majority of patients. Unlike other reports, there were more women receiving more potent anti-dyslipidemic therapy. Nevertheless, women showed a poor control of LDL-concentration after three months of ACS and a similar control after 1-year.

The relationship between pulse pressure with plasma PCSK9 and interleukin-6 among patients with acute ischemic stroke and dyslipidemia

Background and purposeA high plasma concentration of proprotein convertase subtilisin/kexin type 9 is characteristic of a prothrombotic state in cardiovascular diseases. Elevated inflammatory markers, such as interleukin-6, are associated with worse outcomes after ischemic stroke. We aimed to study the role of plasma PCSK9 and IL-6 in acute ischemic stroke with dyslipidemia. MethodsWe divided 123 enrolled patients with first-ever acute ischemic stroke into normotensive and high blood pressure groups and further into high and low pulse pressure subgroups. Clinical characteristics and inflammatory and metabolic parameters, including plasma PCSK9 and IL-6, were recorded. ResultsAfter the analysis of the normotensive and BP groups, there were positive correlations between PP and carotid stenosis (P = 0.031) and plaque numbers (P = 0.013) and between National Institute of Health Stroke Scale scores (P = 0.019) and carotid stenosis severity (P = 0.021) and resistance index (P = 0.04). There was a significant association between plasma cholesterol and PCSK9 (P = 0.044) in the low PP subgroup and IL-6 (P = 0.042) in the high PP subgroup. ConclusionsOur findings indicated that plasma PCSK9 levels were associated with the low PP subgroup, while IL-6 was associated with the high PP subgroup. Dyslipidemia control is also necessary for those who had a stroke and who have high PP. Further investigation to assess the role of PCSK9 and IL-6 in patients with stroke is required for early treatment and secondary prevention.

Control of dyslipidemia in the prevention of recurrent ischemic cerebrovascular accidents (expert opinion)

On July 6, 2022, an interdisciplinary meeting of the Expert Council was held on the topic "Control of dyslipidemia in the prevention of acute and recurrent ischemic cerebrovascular accidents". The conclusion of the Expert Council was that after verification of a lipid metabolism abnormality, in patients with ischemic stroke (IS) and transient ischemic attack (TIA) it is recommended to start or continue statin therapy as early as possible. For secondary prevention of IS, it is necessary to achieve the target level of low-density lipoprotein cholesterol (LDL-C) set for each category of cardiovascular risk, with consistent administration of the maximum tolerated dose of statins with biochemical monitoring of the effectiveness and safety of therapy in the interval of 4–12 weeks. The insufficient effectiveness of statins requires the inclusion of ezetimibe therapy and the decision to increase the dose of statins; in case of intolerance to statins and / or contraindications to their administration, early administration of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: evolocumab, alirocumab – or an PCSK9 synthesis inhibitor, inclisiran, should be considered. At a LDL-C level of &gt;5.0 mmol/l in patients of the extreme or very high risk group who have had atherothrombotic IS / TIA, necessary administration of a combination including a statin, ezetimibe and an PCSK9 inhibitor (evolocumab, alirocumab) or a PCSK9 synthesis inhibitor (inclisiran) should be considered as early as possible.

A STUDY ON FASTING LIPID PROFILE IN NONADIABETIC STROKE PATIENTS

Objectives: To study serum fasting lipid profile in patients with acute ischaemic stroke &amp; to determine the significant correlation between them. To assess the role of aggressive control of dyslipidemia on recovery of stroke. Design: Prospective study. Setting: Patients admitted with Ischemic stroke into the Acute Medical Care Unit and Medical Wards in the department of General Medicine, SAIMS Hospital Indore, from December 2019 to November 2021, were taken for the study. Patients were subjected to a Fasting lipid profile at presentation and followed- up at 12 weeks and rechecked the fasting lipid profile and correlated with the recovery of stroke. Participants: A total of 50 Ischaemic stroke patients- 33 males and 17 females, participated. All subjects were above 50 years. Patients with suspected emboli of cardiac origin, haemorrhagic stroke, diabetes and h/o of head injury/usage of anticoagulant drugs were excluded from the study. None of the patients was on diet (or) other modifications to lower plasma lipid levels. Results: S.T.C was abnormal in 11 patients at onset and 8 pts after three months of statin therapy. TG was abnormal in 34 patients at the beginning and 35 pts after three months of treatment. LDL was abnormal in 32 patients at the beginning and 20 pts after three months of statin therapy. HDL was abnormal in 38 patients at onset and 35 pts after three months of treatment. VLDL was abnormal in 34 pts at the beginning &amp; 35 pts after three months of statin therapy. After three months, the MRS score of most of the patients was 0 -1(21 pts), followed by a score of 0 (15 pts). Correlation between mNIHSS score and lipid profile showed a significant clinical improvement with reduction in the LDL levels &amp; the corresponding p- value is .000, which is highly effective. Correlation between MRS score and lipid profile showed a good clinical outcome with a reduction in LDL levels &amp; the corresponding p-value is 0.26, which is substantial. Conclusion: This study shows that higher levels of S.T.C, TG, LDL, VLDL is not the only significant risk factor for the occurrence of ischaemic CVD. A decrease in LDL levels shows significant improvement in clinical outcomes.

Cinnamon as a Complementary Therapeutic Approach for Dysglycemia and Dyslipidemia Control in Type 2 Diabetes Mellitus and Its Molecular Mechanism of Action: A Review

The scientific evidence that cinnamon may exert beneficial effects on type 2 diabetes mellitus due to the biological activity of its bioactive compounds has been increasing in recent years. This review provides an overview of the effects of cinnamon on clinical parameters of diabetes and summarizes the molecular mechanisms of action of cinnamon on glucose and lipid metabolism. Search criteria include an electronic search using PubMed, Medline, and Cochrane Library databases. English literature references from 2000 up to 2022 were included. Following title and abstract review, full articles that met the inclusion criteria were included. The results from the available evidence revealed that cinnamon improved glycemic and lipidemic indicators. Clinical trials clarified that cinnamon also possesses an anti-inflammatory effect, which may act beneficially in diabetes. Based on in vitro and in vivo studies, cinnamon seems to elicit the regulation of glucose metabolism in tissues by insulin-mimetic effect and enzyme activity improvement. Furthermore, cinnamon seems to decrease cholesterol and fatty acid absorption in the gut. The current literature search showed a considerable number of studies on diabetic subjects. Some limitations in comparing published data should be highlighted, including variability in doses, extracts and species of cinnamon, administration forms, and antidiabetic therapy.

Prehospital Care of Coronary Artery Disease and Its Major Risk Factors in Geropsychiatric Inpatients.

Older adults with serious mental illness have a high prevalence of coronary artery disease and of its major risk factors, that is, arterial hypertension, dyslipidemia, and diabetes mellitus. The prevalence and clinical control of these conditions have not been compared in geropsychiatric inpatients with dementia versus those with mood or psychotic disorders. What is the prevalence and acuity of coronary artery disease, arterial hypertension, dyslipidemia, and diabetes mellitus among patients with dementia, mood, and psychotic disorders admitted for geropsychiatric care? Patients 65 years of age or older were identified in a cohort of 1000 patients consecutively admitted over a 3-year period to the geropsychiatric unit of a 200-bed mental health hospital in suburban New York. All patients had a structured clinical and laboratory evaluation within 72 hours of admission. Primary psychiatric diagnoses, medical history, the frequency of poorly controlled cardiometabolic comorbidity requiring an immediate change in the management plan, and the Charlson Comorbidity Index (CCI). The 65 years and older patient sample (N = 689) had a mean age of 74.8 years, and 58.8% of the subjects were women. The 205 patients with dementia were older ( P < 0.001) than the 337 patients with mood disorders and the 147 patients with psychotic syndromes. The numbers of medical conditions and the CCI after exclusion of dementia were similar in patients with dementia versus patients without dementia. A substantial number of patients had poorly controlled arterial hypertension (51.2%), dyslipidemia (25.4%), diabetes (24.2%), and coronary artery disease (15.4%). Patients with dementia had a lower prevalence of poorly controlled dyslipidemia ( P = 0.0006), diabetes ( P = 0.0089), and coronary artery disease ( P = 0.045). Compared with mood or psychotic disorder, a diagnosis of dementia with behavioral disturbance seemed to be associated with better control of coronary artery disease, dyslipidemia, and diabetes mellitus in geropsychiatric inpatients.

Post-transplant Diabetes Mellitus: What Physicians Need to Know.

Post-transplant diabetes mellitus (PTDM) is a common problem among solid organ transplant recipients contributing to morbidity and affecting patient as well as graft survival adversely. It can occur at any period following transplantation, but maximum incidence is observed in the first few months, with a second peak after a few years after transplantation. The pathogenesis is complex and poorly understood, however, it is associated with both dysfunctional beta-cells and insulin resistance. Both nonpharmacologic and antidiabetic therapies are important for adequate glycemic control. This point of view article provides a short review on PTDM in solid organ transplantation (SOT) recipients from a general physician's perspective.

Prevalence, awareness, treatment, and control of dyslipidemia and associated factors among adults in Jordan: Results of a national cross-sectional survey in 2019

Dyslipidaemia is increasing with low awareness and treatment in low resourced countries.The aim of the study was to evaluate the prevalence, distribution, and correlates of dyslipidaemia and its awareness, treatment, and control among people (18–69 years) in Jordan.In a national cross-sectional survey, a total of 3,132 individuals (mean age: 41.7 years) that took part in the Jordan cross-sectional STEPS survey in 2019 and had complete lipid measurements. Dyslipidemia was defined using the guidelines of the Adult Treatment Panel III.The prevalence of dyslipidemia was 81.6%, 74.0% low high-density lipoprotein cholesterol (HDL-C), 28.2% high triglyceride (TG), 10.1% high total cholesterol (TC) and 8.7% high low-density lipoprotein cholesterol (LDL-C). Among those with dyslipidaemia, 9.3% were aware. Among those who knew, the proportion of lipid-lowering drug treatment was 50.3%, and among those taking lipid-lowering drugs, 25.4% had their dyslipidaemia controlled. In adjusted logistic regression, in both sexes, overweight (AOR: 2.14, 95% CI: 1.49–3.36), obesity (AOR: 2.47, 95% CI: 1.55–3.94), diabetes (AOR: 2.63, 95% CI: 1.30–5.34) were positively and moderate physical activity (AOR: 0.60, 95% CI: 0.37–0.95) was negatively associated with prevalence of dyslipidemia. Older age, overweight, obesity, hypertension, diabetes, and cardiovascular disease were positively associated, and moderate physical activity was negatively associated with awareness of dyslipidemia.Four out of five adults in Jordan had dyslipidaemia and less than one in ten were aware. Several factors associated with the prevalence, awareness, and treatment of dyslipidaemia were identified that can be used to target public health interventions.

The Association between Hypertriglyceridemia and Colorectal Cancer: A Long-Term Community Cohort Study in Taiwan.

(1) Background: Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer deaths worldwide. It often diagnosed at advanced stages, and with increasing incidence at younger generation. CRC poses a heavy financial burden and a huge public health challenge nowadays. Lipoproteins and serum lipids may have an influence on carcinogenesis by making oxidative stress, inflammation, and insulin resistance. Dyslipidemia plays a potential role in the risk of CRC. The purpose of this study is to use nationally representative samples to determine epidemiologic characteristics of CRC in the Taiwanese population, and to evaluate the associations between baseline levels of lipid profile and their effect on risk of colorectal cancer (CRC) comprehensively and quantitatively. The control of dyslipidemia in primary and secondary prevention may reduce the disease burden of CRC. (2) Methods: This is a nationwide long-term community-based prospective cohort study. Data were retrieved from the nationwide population-based Taiwanese Survey on Hypertension, Hyperglycemia and Hyperlipidemia (TwSHHH). Variables were estimated by the Cox proportional hazards model which was then further adjusted for age. We also calculated the relative ratios (RRs) of CRC for joint categories of serum cholesterol, triglyceride (TG), low-density lipoproteins cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) level, and to examine their combined effect and statistical interactions. (3) Results: Male, age, waist circumference, diabetes mellitus (DM), high TG, high cholesterol level, smoking history, and metabolic syndrome were proved to increase the risk of CRC. In addition, DM patients with a TG level ≥150 mg/dL and cholesterol ≥180 mg/dL had a 4.118-fold higher risk of CRC as compared with a TG level <150 mg/dL and cholesterol level <180 mg/dL, which was a significant difference (95% CI, 1.061–15.975; p = 0.0407). (4) Conclusions: Patients with DM should control TG and cholesterol level through diet, exercise, or taking medications more aggressively, not only for preventing cardiovascular disease, but also for first prevention of CRC. The study can be valuable for the clinicians and policy makers to implement more precisely goals about dyslipidemia management.

National high prevalence, and low awareness, treatment and control of dyslipidaemia among people aged 15–69 years in Mongolia in 2019

The aim of the study was to evaluate the prevalence, distribution and correlates of dyslipidaemia among people (15–69 years) in Mongolia. National data were analyzed from 4,895 individuals (15–69 years, median age = 35 years) that took part in the Mongolia cross-sectional STEPS survey in 2019, and had complete lipid measurements. Dyslipidaemia was defined using the guidelines of the Adult Treatment Panel III. The prevalence of dyslipidaemia was 58.6%, 31.7% high triglycerides (TG), 26.9% high low-density lipoprotein cholesterol (LDL-C), 26.9% high total cholesterol (TC) and 14.6% low high-density lipoprotein cholesterol (HDL-C). Among those with dyslipidaemia, 6.2% were aware. Among those who were aware, the proportion of lipid-lowering drug treatment was 18.9% and among those who took lipid-lowering drugs, 21.5% had their dyslipidaemia controlled. In adjusted logistic regression, older age (40–69 years) (AOR: 1.19, 95% CI 1.02–1.40), urban residence (AOR: 1.24, 95% CI 1.04–1.48), obesity call II (AOR: 2.89, 95% CI 2.29–3.66), hypertension (AOR: 1.33, 95% CI 1.11–1.59), and diabetes (AOR: 1.62, 95% CI 1.20–2.18) were positively, and male sex (AOR: 0.84, 95% CI 0.72–1.00) was negatively associated with dyslipidaemia prevalence. Six in ten Mongolians 15 years and older had dyslipidaemia. Several factors associated with dyslipidaemia that can be used to target public health interventions were identified.

Statins, Fibrates and Myopathy: pathophysiological mechanism, risk factors and laboratory markers / Estatinas, Fibratos e Miopatia: mecanismos fisiopatológicos, fatores de risco e marcadores laboratoriais

With the increasing life expectancy of the world population, the elderly experiences the occurrence of multiple chronic diseases, a phenomenon called multimorbidity. Such condition induces the need for the elderly to engage in combined pharmacological treatments, giving rise to polypharmacy, leading to the often unnecessary and inadequate consumption of some drugs. Among these, we can mention fibrates and statins, widely used in the control and treatment of dyslipidemia. Both classes of drugs present as the main adverse effect of concern the genesis of myalgias and myositis, with evolution to rhabdomyolysis. In view of the above, this study aimed to understand the mechanism responsible for inducing muscle damage in the administration of these drugs, also considering the factors that favor their appearance and the laboratory markers used for diagnostic purposes. This work was carried out from a bibliographic review using scientific articles published in English, Portuguese and Spanish, available in the PubMed, Scielo, LILACS and Google academic databases.

A STUDY ON FASTING LIPID PROFILE IN NON-DIABETIC STROKE PATIENTS

Objectives: To study serum fasting lipid profile in patients with acute ischaemic stroke &amp; to determine the significant correlation between them. To assess the role of aggressive control of dyslipidemia on recovery of stroke. Setting: Patients admitted with Ischemic stroke into the Acute Medical Care Unit and Medical Wards in the department of General Medicine, SAIMS Medical Indore, from December 2019 to November 2021, were taken for the study. Patients were subjected to a Fasting lipid profile at presentation and followed– up at 12 weeks and rechecked the fasting lipid profile and correlated with the recovery of stroke. Participants: A total of 50 Ischaemic stroke patients- 33 males and 17 females, participated. All subjects were above 50 years. Patients with suspected emboli of cardiac origin, haemorrhagic stroke, diabetes and h/o of head injury/usage of anticoagulant drugs were excluded from the study. None of the patients was on diet (or) other modifications to lower plasma lipid levels. Results: S.T.C was abnormal in 11 patients at onset and 8 pts after three months of statin therapy. TG was abnormal in 34 patients at the beginning and 35 pts after three months of treatment. LDL was abnormal in 32 patients at the beginning and 20 pts after three months of statin therapy. HDL was abnormal in 38 patients at onset and 35 pts after three months of treatment. VLDL was abnormal in 34 pts at the beginning &amp; 35 pts after three months of statin therapy. After three months, the MRS score of most of the patients was 0 -1(21 pts), followed by a score of 0 (15 pts). Correlation between mNIHSS score and lipid profile showed a significant clinical improvement with reduction in the LDL levels &amp; the corresponding p- value is .000, which is highly effective. Correlation between MRS score and lipid profile showed a good clinical outcome with a reduction in LDL levels &amp; the corresponding p-value is 0.26, which is substantial. Conclusion: This study shows that higher levels of S.T.C, TG, LDL, VLDL is not the only significant risk factor for the occurrence of ischaemic CVD. A decrease in LDL levels shows significant improvement in clinical outcomes.

Association of Vitamin D deficiency with dyslipidemia, glycemic control and microalbuminuria in patients with type 2 Diabetes mellitus in Qatar

Background: Type 2 diabetes mellitus has been found to be associated with 25(OH)D (vitamin D) deficiency. The aim of this study was to the prevalence of vitamin D deficiency in T2DM patients in Qatar and the correlation between vitamin D deficiency and other variables such as dyslipidemia and glycemic control and microalbuminuria. Methods: This retrospective cross-sectional analytical study was carried out at the Hamad General Hospital medical outpatient clinic, in which adult patients (? 18 years) with type 2 DM were involved, between January 1, 2018, and July 31, 2018. Ethical approval was obtained from medical research committee. &#x0D; Results: We recruited 400 subjects with type 2 diabetes mellitus. Their mean age was 58.97±10.32 years and the majority were women (52.0%) and Arabs (69.5%). The mean duration of type 2 diabetes diagnosis was 14.94±8.99 years and mean. The prevalence of vitamin D deficiency was 29.5%. A comparison between vitamin D deficiency and non-vitamin D deficiency groups, showed a statistically significant difference in terms of fasting blood sugar (P&lt;0.001), random blood sugar (P&lt;0.001), HBA1c (P&lt;0.001), total cholesterol (P=0.001), LDL (C) (P=0.004), HDL (C) (P&lt;0.001), triglyceride (P&lt;0.001), and Urinary Albumin Excretion Rate (P=0.007). Data analysis showed that a significant negative correlation was found between vitamin D level and fasting blood sugar (r= -0.208, P&lt;0.001), random blood sugar (r= -0.20, P&lt;0.001), HBA1c (r= -0.260, P&lt;0.001), total cholesterol (r= -0.218, P&lt;0.001), LDL (C) (r= -0.176, P=0.004), triglyceride (r= -0.342, P&lt;0.001), and Urinary Albumin Excretion Rate (r= -0.184, P=0.007). Conclusion: Our study showed a significant correlation between vitamin D deficiency and the poor control of T2DM, dyslipidemia, and microalbuminuria. The results emphasize the importance of monitoring vitamin D status in high-risk populations.

Selected Species of the Cucurbitaceae Family Used in Mexico for the Treatment of Diabetes Mellitus.

In Mexico, Diabetes mellitus (DM) is a serious health problem, and although the current pharmacological treatments for DM such as insulin and oral hypoglycemics are available, the Mexican population continues to use medicinal plants in the treatment of DM. The antidiabetic properties of the plant species that belong to the Cucurbitaceae family has already been recognized worldwide. Since Mexico is one of the most important centers of diversity of Cucurbitaceae, the present work contributes to the review of the most used species of Cucurbitaceae in the treatment of DM in Mexico. The reviewed species (Cucurbita ficifolia, C. maxima, C. moschata, C. pepo, Ibervillea sonorae, Sechium edule, Citrullus lanatus, Cucumis melo, and C. sativus) revealed that the antidiabetic effects exerted are effective in a number of mechanisms involved in the complex pathogenesis of DM: hypoglycemic, antioxidant, anti-inflammatory, anti-obesity, protective effects on diverse organs and cells, as well as in the control of dyslipidemias; furthermore, the select species of the Cucurbitaceae family could also be essential components of diets for the control of DM in patients with the disease. Thus, the Cucurbitaceae species selected in the present work represent a source of antidiabetic agents that perhaps establish the bases for novel clinical treatments.

Investigation on status of dyslipidemia in Chinese females aged 35 years or above

Objective: To investigate the prevalence, awareness, treatment and control status of dyslipidemia among females aged ≥35 years old across China. Methods: Participants were selected by stratified multistage random sampling method in the "Twelfth Five-Year Plan" National Science and Technology Support Project "Survey on the Prevalence of Important Cardiovascular Diseases and Key Technology Research in China" project. This study is a retrospective, cross-sectional study. A total of 17 418 females aged 35 years and over were included in the current study. The basic information such as age, medical history and menopause was collected by questionnaire. The blood lipid parameters were derived from clinical laboratory examinations. The prevalence of dyslipidemia and the rate of awareness, treatment, and control of dyslipidemia were analyzed in females aged 35 years and over. Results: The age of participants was (56.2±13.0) years old, and the prevalence of dyslipidemia was 33.1% (5 765/17 418). The prevalence rates of high total cholesterol, hypertriglyceridemia, low HDL-C and high LDL-C were 9.7% (1 695/17 418), 11.1% (1 925/17 418), 10.9% (1 889/17 418) and 7.3% (1 262/17 418), respectively. The prevalence of dyslipidemia increased with age and the prevalence of dyslipidemia in women who were not married, Han, menarche age>16 years, obesity, central obesity, alcohol consumption, diabetes, hypertension and family history of cardiovascular disease were higher than those without such characteristics (P<0.05). There were 10 432 (59.9%) menopausal females in this cohort and prevalence of dyslipidemia of these participants was 38.8% (4 048/10 432), which was higher than that of non-postmenopausal females (24.6%, 1 717/6 986) (P<0.05). The awareness rates, treatment rates and control rates of dyslipidemia were 33.9% (1 953/5 765), 15.1% (870/5 765) and 2.5% (143/5 765) respectively among females aged 35 years and over in China. Conclusion: The prevalence of dyslipidemia in Chinese females aged 35 years and over is high, and its awareness, treatment, and control rates need to be optimized.